Pharmacokinetics, Pharmacodynamics, & Drug Metabolism Community

 View Only

OSD on May 30th: Multi-omics in Precision Medicine (Part 1)

  • 1.  OSD on May 30th: Multi-omics in Precision Medicine (Part 1)

    Community Leadership
    Posted 05-01-2024 16:35

    The Biomarkers and Precision Medicine (BPM) Community is hosting a series of Open Scientific Discussions (OSDs) on Multi-omics in Drug Development.  Please join us for the first OSD in the series hosted on May 30th, 12 - 1 pm ET:

    Part 1: Multi-omics in Precision Medicine

    ·       What are the factors that influence novel biomarker identification and characterization using multi-omic approaches?

    ·       What are key considerations when choosing between the various multi-omic technologies?

    ·       Case studies on the use of multi-omics to support precision medicine will be presented. 

    Discussion Leaders:

    Matt Blatnik (AbbVie) and Christina Ebert (BMS)

    Organized by:  Jurre Kamphorst (Olaris), Iris Qiu (Novartis), Ayuko Ota-Selik and Jianing Zeng (BMS)

     

    We start at 12:00 ET sharp. To avoid interruptions, please dial in before noon and mute yourself until Q&A starts.

    (Please remain on mute unless asking questions)

    When: Thurs, May 30, 2024, 12 pm – 1 pm ET

    WherePlease join from your computer, tablet or smartphone.
    https://global.gotomeeting.com/join/305789893

    You can also dial in using your phone.
    United States: 
    +1 (872) 240-3412
    Access Code: 305-789-893
    Join from a video-conferencing room or system.
    Dial in or type: 
    67.217.95.2 or inroomlink.goto.com
    Meeting ID: 305 789 893
    Or dial directly: 
    [email protected] or 67.217.95.2##305789893
    New to GoToMeeting? Get the app now and be ready when your first meeting starts:
    https://global.gotomeeting.com/install/305789893

    Please feel free to share with colleagues who may be interested in this topic.

     

    Thank you,

    The AAPS BPM Community Leadership Team

    #biomarker  #precision_medicine  #Proteomics  #OpenScientificDiscussions  #OSD  #MachineLearning



    ------------------------------
    Karen Quadrini, PhD
    Director, Clinical Biomarkers
    Prothena Biosciences
    Brisbane, CA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------